Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00618605
- Testing
- Ad26.ENVA.01 HIV-1 vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 and Hepatitis C Co-Infection
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes.
- Trial name
- NCT00665353
- Testing
- pioglitazone, peginterferon, ribavirin
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
IDV Associated Nephrotoxicity
Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity
Efficacy and safety of a saquinavir (SQV) based regimen in HIV-1 infected Thai patients who have chronic indinavir (IDV) associated nephrotoxicity.
- Trial name
- NCT00477048
- Testing
- Saquinavir
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)
EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication.
- Trial name
- NCT04120415
- Testing
- Vaccine and vedolizumab (Entyvio)
- Where
- 4 sites in France, Switzerland and 1 more
- Volunteers
- 2 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2
To evaluate the safety and immunological effects of polyethylene glycolated-interleukin-2 (PEG-IL-2) on asymptomatic (without symptoms) HIV-seropositive patients who are taking zidovudine (AZT).
- Trial name
- NCT00002017
- Testing
- Interleukin-2, Polyethylene Glycolated
- Where
- United States
- Sponsor
- Rockefeller University
HIV-1
PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
BACKGROUND: Since 1996 the combination of three or more drugs has been the mainstay of human immunodeficiency virus (HIV) treatment.
- Trial name
- PIONA (NCT01192035)
- Testing
- Efavirenz or Nevirapine, Ritonavir-boosted lopinavir
- Where
- Guinea-Bissau
- Volunteers
- 400 people
- Sponsor
- University of Aarhus
HIV Infections
A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]
The purpose of this study is to see if a computer counseling tool helps Spanish-speaking people living with HIV to have safer sex and to do well on their HIV medicines.
- Trial name
- CARE+ Spanish (NCT01013935)
- Testing
- CARE+ Spanish computer counseling session, CARE+ Spanish brief computer risk assessment session
- Where
- United States
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- New York University
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to determine if a combination anti-HIV drug treatment regimen of indinavir plus lamivudine (3TC) plus zidovudine (ZDV) is effective in treating HIV and in reducing the chances of passing HIV from…
- Trial name
- NCT00000944
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Subjects
Observational Study of the Preventive Trial With HIV-1 Tat Protein
The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe, well tolerated and immunogenic.
- Trial name
- ISS OBS P-001 (NCT01024764)
- Where
- 3 sites in Italy
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Istituto Superiore di Sanità
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00750009
- Testing
- educational intervention
- Where
- 4 sites in United States
- Volunteers
- 583 people
- Sponsor
- Case Comprehensive Cancer Center
HIV-1 Infection
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
The objective is to obtain plasma samples from Human Immunodeficiency Virus Type 1 (HIV-1) infected individuals that have viral loads across the dynamic range of the Aptima HIV-1 assay.
- Trial name
- NCT02026752
- Where
- 9 sites in United States
- Volunteers
- 468 people
- Sponsor
- Gen-Probe, Incorporated
HIV Infections
Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to an alphavirus replicon, HIV-1 subtype C gag vaccine, AVX101, in HIV uninfected adults in the United States, South Africa, and Botswana.
- Trial name
- NCT00097838
- Testing
- AVX101
- Where
- 8 sites in United States, Botswana and 1 more
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
Infection, Human Immunodeficiency Virus
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood.
- Trial name
- NCT00920426
- Testing
- GSK1265744 30mg, GSK1265744 5mg
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- ViiV Healthcare
HIV
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
There is evidence that early and aggressive treatment with antiretroviral drugs can prevent the loss of immune cell function that accompanies HIV infection.
- Trial name
- NCT00039689
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, HIV-1 Infection
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and…
- Conditions
- HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)
- Trial name
- RIFAMARA (NCT01894776)
- Testing
- Rifabutin, Maraviroc
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Human Immunodeficiency Virus, Dolutegravir
A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients
Current HIV treatment guidelines recommend a combination of drugs for the maintenance of antiretroviral therapy (ART). Simplification is considered critical to further scale-up of treatment, to support retention in care and to…
- Conditions
- Human Immunodeficiency Virus, Dolutegravir, Monotherapy, Treatment Efficacy
- Trial name
- MONODO (NCT02572947)
- Testing
- Dolutegravir
- Where
- Switzerland
- Volunteers
- 8 people
- Sponsor
- Calmy Alexandra
HIV-1
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Background: Antiretroviral therapy (ART) can suppress HIV to undetectable levels in people, but the virus rebounds quickly if the drug treatment is stopped; this is because HIV can remain dormant in a pool of blood cells called…
- Trial name
- NCT05612178
- Testing
- 3BNC117-LS, 10-1074-LS, Sterile Saline
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
The primary objective of this study is: To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of serum human…
- Trial name
- CHEER (NCT00529243)
- Testing
- raltegravir
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kaiser Permanente
Infection, Human Immunodeficiency Virus, HIV Infections
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve…
- Trial name
- SAILING (NCT01231516)
- Testing
- GSK1349572, Raltegravir
- Where
- 180 sites in United States, Argentina and 18 more
- Volunteers
- 724 people
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.